| To observe the effect of the Garlicin injection in the treatment of Ⅲ prostatitis pain, and to discuss the change of prostatic fluid p38MAPK, COX-2. Methods: Total 90 patients with Ⅲ prostatitis pain were admitted to our department from July 2015 to February 2016, and then randomly divided into control group and observation group, with 45 cases in each group. Control group was given Celecoxib tablets, 2 / day, 1/piece, for 14 days, the observation group were injected by Garlicin with normal saline bolus, the clinical efficacy of the treatment, all clinical score, adverse drug reactions were observed 14 days after treatment, as well as other changes in p38MAPK, COX-2, IL-6, TNF-α. Results: 1) The effective rate of the observation group after treatment was 86.67%, significantly higher than the control group’s 68.89% (P<0.05)；2) Each score in two groups had no significant difference before treatment (P>0.05), but after treatment, the NIH-CPSI, QOL decreased IIEF-5 increased in both two groups, but the changes were more obvious in the control group, the differences were statistically significant (P<0.05); 3) As for the adverse reactions, the control group had 10 cases (33.00%) but observed 4 cases (8.80%) , which was significantly higher than the observation group (P<0 .05); 4)Before treatment, the differences on prostatic fluid p38MAPK, COX-2 and plasma IL-6, TNF-α level were not statistically significant (P>0.05). But 14 days after treatment, the index decreased in both two groups, but the observation group decreased more significantly (P<0.05). Conclusion: The Garlicin injection can achieve significant clinical efficacy, with less adverse reactions than conventional treatment, which is worthy to be promoted in clinical practice. Meanwhile, the drug may work on the level of p38MAPK、COX-2、IL-6、TNF-α by reducing inflammation factors. |
